Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rhuMAb IFNalpha · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| rhuMAb IFNalpha | DRUG | Intravenous repeating dose |
Inclusion Criteria: * For patients with reproductive potential (males and females), use of a reliable means of contraception (e.g., hormonal contraceptive, patch, vaginal ring, intrauterine device, physical barrier) throughout their participation in the study * Diagnosis of SLE according to current...
Top 20 of 34 competitors
rhuMAb IFNalpha was studied for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease. It was developed by Roche Holding AG as an investigational monoclonal antibody. The clinical program evaluated it in adults with SLE, but the drug has not been approved for any indication.
rhuMAb IFNalpha is a monoclonal antibody designed to target interferon-alpha. By binding to interferon-alpha, it aims to neutralize this cytokine, which is thought to contribute to the inflammation and immune dysregulation seen in systemic lupus erythematosus. The target class is an antibody.
rhuMAb IFNalpha is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche conducted the clinical research for this monoclonal antibody in systemic lupus erythematosus.
rhuMAb IFNalpha is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA or any regulatory agency for systemic lupus erythematosus or any other condition.
rhuMAb IFNalpha has been evaluated in one completed Phase 1 clinical trial, NCT00541749, titled "A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus." The trial enrolled 60 adults, was randomized and double-blind, and had no active trials at the time of this report.